Terminal Complement Inhibition: Promising Resul...

By HEOR Staff Writer

April 24, 2026

Terminal complement inhibition with Ultomiris (ravulizumab) delivered a statistically significant and clinically meaningful reduction in proteinuria at week 34 in adults with immunoglobulin A nephropathy (IgAN) at high risk of progression. Accordi...
Advancing Multicenter AKI Prediction: Benefits of Collaborative Models Over L...
Advancements in HIV Two-Drug Regimen: FDA Approves IDVYNSO for Virologically ...
Progress and Challenges in the FDA Accelerated Approval Pathway: A Policy Roa...
Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
Effective Hypertension Control Interventions in Underserved Populations
Advancing B7-H3 Targeted Therapy for Relapsed Extensive-Stage Small Cell Lung...
Advancing Access: Generic Dapagliflozin Approval Enhanced for Type 2 Diabetes...
Utah’s AI Medication Prescribing Risks: Navigating the Challenges of Au...
Expansion of Community Health Programs by Novartis to Tackle Global Health Di...
Differentiated Visceral Fat Reduction in Early Trials of WVE-007
Impact of Insulin Copay Caps on Medicare Beneficiary Health and Spending
Advancements in Immunotherapy for Hepatocellular Carcinoma: EMERALD-3 Trial R...